KRON
Price:
$0.95
Market Cap:
$57.32M
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 ...[Read more]
Industry
Biotechnology
IPO Date
2020-10-09
Stock Exchange
NASDAQ
Ticker
KRON
According to Kronos Bio, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 8.32. This represents a change of 2.79% compared to the average of 8.09 of the last 4 quarters.
The mean historical Current Ratio of Kronos Bio, Inc. over the last ten years is 19.90. The current 8.32 Current Ratio has changed 4.08% with respect to the historical average. Over the past ten years (40 quarters), KRON's Current Ratio was at its highest in in the March 2021 quarter at 35.91. The Current Ratio was at its lowest in in the March 2019 quarter at 0.
Average
19.90
Median
18.44
Minimum
7.24
Maximum
34.60
Discovering the peaks and valleys of Kronos Bio, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 330.26%
Maximum Annual Current Ratio = 34.60
Minimum Annual Increase = -55.42%
Minimum Annual Current Ratio = 7.24
Year | Current Ratio | Change |
---|---|---|
2023 | 7.24 | -36.33% |
2022 | 11.37 | -55.42% |
2021 | 25.51 | -21.89% |
2020 | 32.65 | -5.61% |
2019 | 34.60 | 330.26% |
The current Current Ratio of Kronos Bio, Inc. (KRON) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
14.71
5-year avg
22.27
10-year avg
19.90
Kronos Bio, Inc.’s Current Ratio is greater than Cyclerion Therapeutics, Inc. (5.07), less than Larimar Therapeutics, Inc. (13.10), greater than Addex Therapeutics Ltd (4.59), greater than Achilles Therapeutics plc (6.04), less than NextCure, Inc. (9.07), greater than CytomX Therapeutics, Inc. (1.04), less than Neoleukin Therapeutics, Inc. (15.33), greater than Spero Therapeutics, Inc. (2.68), greater than Assembly Biosciences, Inc. (2.36), less than Replimune Group, Inc. (10.11), greater than Nuvectis Pharma, Inc. (2.74), greater than Lyra Therapeutics, Inc. (3.64), greater than Gossamer Bio, Inc. (6.74), less than Crinetics Pharmaceuticals, Inc. (16.38), greater than Inhibrx Biosciences, Inc. (4.70), less than Merus N.V. (8.32), less than Lyell Immunopharma, Inc. (13.43), greater than Generation Bio Co. (6.34), less than Erasca, Inc. (11.00), greater than C4 Therapeutics, Inc. (6.31), less than Edgewise Therapeutics, Inc. (26.35),
Company | Current Ratio | Market cap |
---|---|---|
5.07 | $8.67M | |
13.10 | $252.67M | |
4.59 | $10.50M | |
6.04 | $40.33M | |
9.07 | $26.35M | |
1.04 | $85.30M | |
15.33 | $8.20M | |
2.68 | $50.31M | |
2.36 | $94.84M | |
10.11 | $929.70M | |
2.74 | $88.49M | |
3.64 | $11.45M | |
6.74 | $194.43M | |
16.38 | $5.00B | |
4.70 | $209.47M | |
8.32 | $2.91B | |
13.43 | $179.85M | |
6.34 | $73.47M | |
11.00 | $701.16M | |
6.31 | $286.59M | |
26.35 | $2.84B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kronos Bio, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Kronos Bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Kronos Bio, Inc.'s Current Ratio?
How is the Current Ratio calculated for Kronos Bio, Inc. (KRON)?
What is the highest Current Ratio for Kronos Bio, Inc. (KRON)?
What is the 3-year average Current Ratio for Kronos Bio, Inc. (KRON)?
What is the 5-year average Current Ratio for Kronos Bio, Inc. (KRON)?
How does the current Current Ratio for Kronos Bio, Inc. (KRON) compare to its historical average?